|
|
Article: Coexistence of acute cellular rejection and lymphoproliferative disorder in a lung transplant patient.
- Article from:
- Archives of Pathology & Laboratory Medicine
- Article date:
- November 1, 2001
- Author:
CopyrightCOPYRIGHT 2001 College of American Pathologists. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Lung transplantation is an established and increasingly available therapeutic intervention for end-stage pulmonary disease. (1) Acute cellular rejection (ACR), with an incidence of 67%, (2) and infections are frequent complications in the first 2 to 3 months following transplantation. During the later posttransplantation period, progressive deterioration of graft function secondary to obliterative bronchiolitis (OB) develops in about 10% to 54% of lung recipients. (3) Obliterative bronchiolitis resulting from chronic rejection usually cannot be successfully treated once it is clinically manifest. For this reason, it represents the most critical threat to the long-term ...
Related newspaper, magazine, and journal articles:
|
|
Article: Dako Receives FDA Approval for Use of EGFR pharmDx(TM) ...
PR Newswire;
October 4, 2006 ;
700+ words
... ... Calif., Oct. 4 /PRNewswire/ -- Dako, the leading provider of pharmDx(TM ... Cetuximab), manufactured by ImClone. Today Dako's EGFR pharmDx(TM) kit remains the ... evidence of EGFR expression with this kit. "Dako is committed to providing the most reliable ...
|
|